How it Works
Treanda is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Treanda is classified as an "alkylating agent."
Treanda causes intra- and inter-strand crosslinks between DNA bases resulting in cell death.
How it’s Administered
TREANDA is available in two formulations, a solution (TREANDA Injection) for IV injection and a lyophilized powder (TREANDA for Injection).
The two different administrations have different concentrations of bendamustine hydrochloride. The concentration of bendamustine hydrochloride in the solution is 90 mg/mL, and the concentration of bendamustine hydrochloride in the reconstituted solution of lyophilized powder is 5 mg/mL. Do not mix or combine the two formulations.
Who Should Take Treanda
Treanda is currently approved for:
- Chronic Lymphocytic Leukemia (CLL) TREANDA® is indicated to treat patients with chronic lymphocytic leukemia. Efficacy relative to first-line therapies other than chlorambucil has not been established
- Non-Hodgkin’s Lymphoma (NHL)TREANDA for Injection is indicated to treat patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen
- Studies have proven the safety and efficacy of bendamustine administered alone or in combination with new drugs in both upfront and relapse/refractory settings of MM patients, including those with renal impairment. Moreover, bendamustine has been successfully used as conditioning for autologous stem-cell transplantation. Finally, the use of bendamustine does not compromise peripheral blood stem-cell collection
Who Shouldn’t Take Treanda
- Patients who are allergic to bendamustine or mannitol
- Pregnant women
- Children under 18
The Most Common Side Effects of Taking Treanda Include:
- Lymphopenia
- Anemia
- Leukopenia
- Thrombocytopenia
- Neutropenia
Commonly Used With
- Pomalidomide
- Dexamethasone
Commonly Being Tested With
- Immunomodulators (IMiDs): Pomalidomide
- Corticosteroids: Dexamethasone
- Alkylating Agents: Melphalan
- Proteasome Inhibitors: Carfilzomib
Learn more about your treatments in Cure Hub
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Anaplastic Large Cell Lymphoma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.